Author of

• 14306

  +

  P2.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 207)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Treatment of Advanced Diseases - NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 14360

    +

    P2.01-054 - Continuation Maintenance Therapy of Pemetrexed and Renal Toxicities (ID 764)

    09:30 - 09:30  |  Author(s): T. Nakanishi
    • Abstract
    • Slides

    Background:
    Pemetrexed is a multitargeted antifolate agent approved for use in the treatment of pleural mesothelioma and non-small cell lung cancer. A recent phase III PARAMOUNT trial has shown that pemetrexed continuation maintenance therapy reduced the risk of disease progression and death compared with a placebo. However, renal toxicities of maintenance therapy of pemetrexed has not been clarified.
    
    Methods:
    We retrospectively evaluated a total of 30 patients who had received 4 cycles of induction therapy with pemetrexed with platinum (cisplatin or carboplatin) regimens with or without bevacizumab followed by more than 4 cycles of pemetrexed (± bevacizumab) maintenance therapy. Estimated creatinine clearance at three different time points (before the induction therapy, after the induction therapy, and after the 4 cycles of maintenance therapy) were analyzed. We also investigated factors significantly associated with deterioration in renal function during pemetrexed maintenance therapy using univariate and multivariate logistic regression analyses.
    
    Results:
    Significant decrease in the mean value of eCcr could be observed during pemetrexed maintenance therapy in both cisplatin and carboplatin groups. Multivariate analysis revealed that cisplatin administration and poor performance status (PS ≥1) were risk factors significantly associated with eCcr decrease.
    
    Conclusion:
    Continuance maintenance therapy of pemetrexed generally could cause renal dysfunction. More attention should be paid to the patients receiving a cisplatin based induction therapy and patients with poor performance status.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.